Cantekin Kenan, Gümüş Hüsniye
Department of Pediatric Dentistry, Faculty of Dentistry, Erciyes University, 38039 Kayseri, Turkey.
Int Sch Res Notices. 2014 Jul 8;2014:819605. doi: 10.1155/2014/819605. eCollection 2014.
Purpose. The purpose of this study was to evaluate clinical and radiographic findings of treatments using a new hemostatic agent (Ankaferd blood stopper (ABS)), as compared to ferric sulfate (FS), when used as a pulpotomy medicament in primary teeth. Materials and Methods. The primary molars (70) were selected from 35 children aged 4 to 6 years. The teeth were randomized into two groups for pulpotomy with the ABS (n = 35) and the FS (n = 35) agents. The patients were recalled for clinical and radiographic evaluation at 3-, 6-, 9-, and 12-month intervals. Results. At the 3- and 6-month clinical and radiographic evaluations, total success rates of 100% were observed in each group. In ABS and FS groups, the clinical success rates, however, reduced to 90.9% and 93.9% at the 9-month examination and 84,8% and 90.9% at the 12-month examination, respectively. Similarly, the teeth in the ABS and FS groups had radiographic success rates of 90.9% and 93.9% at 9 months and 84.8% and 87.8% at 12 moths, respectively. Conclusion. Although the findings indicated that ABS agents may be useful agents for pulpotomy medicament, further long-term and comprehensive histological investigations of ABS treatments are necessary.
目的。本研究的目的是评估一种新型止血剂（安卡福得血速停（ABS））与硫酸铁（FS）相比，在乳牙活髓切断术中用作药物时的临床和影像学表现。材料与方法。从35名4至6岁儿童中选取70颗乳磨牙。将牙齿随机分为两组，分别用ABS（n = 35）和FS（n = 35）进行活髓切断术。在3、6、9和12个月的间隔期对患者进行召回，进行临床和影像学评估。结果。在3个月和6个月的临床和影像学评估中，每组的总成功率均为100%。然而，在ABS组和FS组中，9个月检查时的临床成功率分别降至90.9%和93.9%，12个月检查时分别降至84.8%和90.9%。同样，ABS组和FS组的牙齿在9个月时的影像学成功率分别为90.9%和93.9%，12个月时分别为84.8%和87.8%。结论。尽管研究结果表明ABS可能是活髓切断术的有效药物，但仍需对ABS治疗进行进一步的长期和全面的组织学研究。
